NRx Pharmaceuticals Wraps Virtual Annual Meeting, Eyes Pivotal 2025 Earnings Call Ahead

3 hours ago 1

MarketBeat

Tue, March 24, 2026 astatine 4:05 AM CDT 5 min read

NRx Pharmaceuticals logo

2025 described arsenic "extraordinarily pivotal": NRx said it is "in the FDA" with astatine slightest 1 cause it hopes could beryllium approved this twelvemonth and is operating revenue-generating clinics treating patients daily.
Stockholders approved each 4 proposals, including the predetermination of Chaim Hurvitz and Michael Taylor arsenic Class I directors, an amendment to the 2021 Omnibus Incentive Plan, ratification of Weinberg & Company arsenic auditor, and a non-binding say-on-pay vote.
Management said the auditor alteration to Weinberg & Company was driven by HOPE Therapeutics' request for a larger steadfast to grip medical-services gross recognition, and the institution volition record last voting results successful a Form 8-K and supply elaborate updates connected its upcoming net league call.
Interested successful NRx Pharmaceuticals, Inc.? Here are 5 stocks we similar better.

5 Biotech stocks tapping into unmet intelligence wellness attraction needs

NRx Pharmaceuticals (NASDAQ:NRXP) held its 2025 yearly gathering of stockholders successful a virtual format, with Chairman Jonathan Javitt calling the gathering to bid astatine 10:00 a.m. Eastern. Javitt said the institution hopes to clasp aboriginal meetings successful idiosyncratic “now that we person objective facilities open,” adding that the enactment wants a venue to amusement stakeholders its day-to-day work.

Javitt served arsenic gathering chairman, portion Chief Financial Officer and Corporate Treasurer Michael Abrams acted arsenic secretary. Early successful the session, absorption noted that attendees were mostly logged successful arsenic guests alternatively than stockholders utilizing power numbers, which constricted the quality to taxable questions done the gathering portal. Ultimately, the institution reported that nary stockholder questions were received during the gathering oregon the little question-and-answer play that followed.

→ Planet Labs: The Satellite Stock That Keeps Shooting to the Moon

Doing Your Holiday Shopping? These Stocks Might Make Great Gifts

In prepared remarks, Javitt said the gathering occurred 1 time earlier the institution planned to denote its yearly net for 2025, and helium encouraged participants to be the forthcoming net league telephone for elaborate updates and progress-related questions.

Javitt characterized 2025 arsenic “an extraordinarily pivotal year” for the company. He said that aft years of probe and development, NRx Pharmaceuticals is “in the FDA with astatine slightest 1 cause that we anticipation tin beryllium approved this year.” He besides said the institution has clinics “treating patients each day,” and described 2025 arsenic the archetypal twelvemonth NRx has operated arsenic a “revenue-generating objective entity” alongside its biotechnology R&D efforts. On the upcoming net call, the institution expects to sermon its advancement toward cause support and wherefore it is optimistic astir establishing “a coagulated fiscal operating past by the extremity of the year,” according to Javitt.

Read Entire Article